Lumina "Old Drug Resurrection": Buy-out from the shire mouth, has been the FDA breakthrough certification.

Just as Britain's Shire first hit luminas Pharmaceuticals () for its huge potential in the field of rare liver disease, Gilead Science () attracted a lot more interest from AstraZeneca in the field of liver disease: gides' famous hepatitis C drug Sofibouvir () sold as much as $100 million in sales, which held Gilead's position as a global pharmaceutical companyAlthough both Lumina and Gilead have been in the same area of liver disease, but the road is not as easy as the outside world thoughtLast month, Professor T.A., a professor at the University of Arizona, released a record of the top liver disease-related drugs in the global drug salesGilead's hepatitis C drug has shrunk to $100 million a year because of the franchise, and the company's annual non-alcoholic fatty hepatitis () product line has failedIt can be seen that large pharmaceutical companies in the field of liver disease drug development has been hit hard is also commonIn addition, Lumina's rare liver disease drug, which had been packaged by Shire, had been in a "frozen period" for years, long-stalled because of a rare concurrent case in an experimentIt wasn't until luminas pharmaceuticals, which founded Lumina Pharmaceuticals in the year, that a new batch of top-line data was "resurrected" in the name of another company, and rebranded and raised hundreds of millions of dollarsThe "resurrection" of the two old drugs, derived from Lumina and re-purchased from shire, is progressing wellClinical trials for children with (for the development of intrafapathic hepatic bile siltation) show that the drug has a significant effect on serum bile acid rise and itching and has resulted in breakthrough therapy certification is currently in advanced clinical studies; Another drug may provide an innovative treatment for adult bile siltation disease and has good data available in clinical trials